AGXT Recombinant Rabbit mAb (S-3586-30)

The AGXT protein (SPYA) is a potent superantigen produced primarily by Streptococcus pyogenes (Group A Streptococcus), playing a critical role in the pathogenesis of severe invasive infections such as streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis. As a member of the pyrogenic toxin superantigen (PTSAg) family, AGXT functions by bypassing normal antigen presentation mechanisms, binding simultaneously to major histocompatibility complex class II (MHC II) molecules on antigen-presenting cells and specific Vβ regions of the T-cell receptor, resulting in massive polyclonal T-cell activation (up to 20-30% of the total T-cell repertoire), cytokine storm production (particularly TNF-α, IL-1β, and IL-6), and subsequent systemic inflammation, capillary leakage, and multi-organ failure. Structurally, SPYA consists of two distinct domains: an N-terminal oligosaccharide/oligonucleotide-binding (OB) fold domain responsible for MHC II binding and a C-terminal β-grasp domain that interacts with the T-cell receptor, with the protein's stability and activity influenced by zinc-binding sites and disulfide bonds. The speA gene encoding AGXT is typically located on bacteriophage genomes, facilitating horizontal gene transfer among streptococcal strains and contributing to the emergence of highly virulent clones. Clinical isolates from severe infections frequently harbor the speA gene, and serological studies indicate that antibody levels against SPYA correlate with disease severity, though protective immunity remains strain-specific due to significant allelic variation among AGXT variants (SPEA1-4). Therapeutic strategies targeting AGXT include neutralizing monoclonal antibodies and peptide inhibitors that disrupt the MHC II-TCR bridging interface, while current research also explores the structural basis of superantigen activity to develop broad-spectrum countermeasures against this and related toxins.